TENX News and Press, Tenax Therapeutics Inc. From 12/29/20

Universal Security Instruments (UUU) +293%.Technical Communications (TCCO) +214%.Koss Corporation (KOSS) +99%.Tenax Therapeutics (TENX) +80%.New Concept Energy (GBR) +58%.IRIDEX Corporation (IRIX) +23%.SOS Limited (SOS) +10% after announcing partnership with Zhonglu P&C Insuranc...

Tenax Therapeutics (TENX): Q3 GAAP EPS of -$0.18 misses by $0.04.Cash, equivalents and marketable securities totaled $8.7M.Press Release For further details see: Tenax Therapeutics EPS misses by $0.04

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the third quarter 2020 and provided a business update. Tenax will share upda...

Acceleron Pharma ([[XLRN]] -1.8%) announces new data from two Phase 2 clinical trials, SPECTRA and PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension ((PAH)).Preliminary results from 10 participants in SPECTRA showed that treated patients experienced substantial i...

HELP Study results presentation will be available online beginning on November 13, 2020 at 9:00 a.m CST Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care ...

Webinar Scheduled for 4:30 pm EST on November 18 Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host a virtual R&D webinar ...

Tenax Therapeutics (TENX) +14% premarket, has amended its existing licensing agreement with Orion Corporation to include the rights to develop and commercialize an oral formulation of levosimendan for use with Type 2 pulmonary hypertension in heart failure patients with preserv...

Tenax gains developmental and commercial rights for a fully-developed oral levosimendan formulation in the U.S. and Canada Oral formulation expected to be used in upcoming Phase 3 registration trial Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceuti...

HELP Study results will be presented on Saturday, October 3, 2020 at 4:30 pm EDT Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced ...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 22 nd Annua...